Evidence map›Paper›PMID 35150345›Full record

ArticleDigestive diseases and sciences2022

Real-World Insurance Claims Analysis of Venous Thromboembolism in Japanese Patients with Inflammatory Bowel Disease.

Mikihiro Fujiya, Tsutomu Kawaguchi, Shoko Arai, Naoki Isogawa, Shintaro Hiro, Fumihiro Matsumoto, Satoshi Yamaguchi, Noritoshi Yoshii, Mashio Nakamura, Katsuyoshi Matsuoka

Open access · hybridAbstract read
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mikihiro FujiyaDivision of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan. fjym@asahikawa-med.ac.jp.ORCID 0000-0002-4321-7774
Tsutomu KawaguchiImmunology & Inflammation Medical Affairs, Pfizer Japan Inc, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Shoko AraiImmunology & Inflammation Medical Affairs, Pfizer Japan Inc, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Naoki IsogawaBiometrics & Data Management, Pfizer R&D Japan, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Shintaro HiroBiometrics & Data Management, Pfizer R&D Japan, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Fumihiro MatsumotoImmunology & Inflammation Medical Affairs, Pfizer Japan Inc, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Satoshi YamaguchiImmunology & Inflammation Medical Affairs, Pfizer Japan Inc, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Noritoshi YoshiiImmunology & Inflammation Medical Affairs, Pfizer Japan Inc, Shinjuku Culture Quint Bldg 3-22-7 Yoyogi Shibuya-ku, Tokyo, 151-8589, Japan.
Mashio NakamuraDepartment of Internal Medicine, Pediatrics and Cardiology, Hidamarinooka Nakamura Medical Clinic, 7-1510 Hidamarinooka, Kuwana, 511-0867, Japan.
Katsuyoshi MatsuokaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura City, Chiba, 285-0841, Japan.
Pfizer (Japan) · JPAsahikawa Medical College Hospital · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD), which encompasses both ulcerative colitis (UC) and Crohn's disease (CD), is a risk factor for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).

aimTo investigate the incidence of, and risk factors for, VTE in patients with IBD in Japan.

methodsThis was a retrospective, non-interventional study in patients with IBD from the Japan Medical Data Center claims database. Incidence rates (IRs; unique patients with events per 100 patient-years) were calculated for VTE, DVT, and PE among the IBD, UC, and CD cohorts. Odds ratios of potential risk factors were calculated by univariate and multivariate analyses in a nested case-control design.

resultsOverall, 16 273 patients with IBD were included: 13 585 with UC and 3443 with CD. VTE events occurred in 1.3%, 1.2%, and 1.9% of patients with IBD, UC, and CD, respectively. In patients with IBD, UC, and CD, IRs of VTE were 0.45, 0.40, and 0.64, respectively, IRs of DVT were 0.42, 0.38, and 0.61, respectively, and IRs of PE were 0.07, 0.07, and 0.11, respectively. In patients with IBD, treatment history (immunomodulators), cardiovascular risk (hypertension, high-density lipoprotein or diabetes mellitus, and history of coronary artery disease or heart failure), malignancy, and undergoing major surgery were identified as potential risk factors for VTE in the multivariate analysis, with similar risk factors reported for patients with UC and CD.

conclusionsThis large study provides insight into the incidence and risk factors for VTE in patients with IBD from Japan.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesPulmonary EmbolismVenous ThromboembolismHumansIncidenceInsurance Claim ReviewJapanLipoproteins, HDLRetrospective StudiesRisk FactorsLipoproteins, HDLIncidenceInflammatory bowel diseasesJapanRisk factorsVenous thromboembolism

Identifiers

PMID35150345
PMCPMC9587926
OpenAlexW4211050396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.